

Oncopeptides (Q3 Update) - Q/Q Growth Only 5%, but 2026 Looks Promising

Redeye comments on Oncopeptides' 3rd quarter report. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Although sales were below our forecast in Q3, we have expectations for higher growth in the coming quarters.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Oncopeptides \(Q3 Update\) - Q/Q Growth Only 5%, but 2026 Looks Promising](#)